Shares of Abbott Laboratories surged 6.3% to $106.48 after the company disclosed that the FDA approved major new capabilities for its implantable heart-failure monitoring sensor — a move that transforms a decade-old clinical tool into a patient-facing digital platform. Abbott had two notable product-driven catalysts this week, including FDA approval for expanded CardioMEMS features, and the stock also benefited from fresh analyst upgrades, with investors still facing a near-term earnings test on October 21.
A Tiny Sensor Gets a Big Software Upgrade
The FDA approved enhancements that, for the first time, allow patients to access their pulmonary artery pressure readings — a measure of blood flow from the heart to the lungs — directly on their smartphones.
The update also includes a software feature that lets doctors set up personalized medication adjustment plans triggered by pressure changes, sending instructions directly to patients through the app. In plain terms: a device that previously only talked to doctors now talks to patients, too — closing the loop on care between office visits.
Heart Failure Monitoring Is the Fastest-Growing Slice of a Booming Market
The U.S. remote cardiac monitoring market was valued at $1.95 billion in 2025, and heart failure monitoring is the fastest-growing application segment, projected to grow at a 13.4% annual rate through 2035.
Abbott's own heart failure sales grew 12.7% in 2025, driven partly by CardioMEMS uptake.
A prior expanded indication already opened the device to an additional 1.2 million eligible U.S. patients. Adding patient engagement software on top of that larger addressable base could accelerate implant volumes and generate recurring digital revenue.
The Rally Looks Justified — But the Valuation Math Still Needs Earnings Proof At $106.48, Abbott now trades at roughly 34× trailing earnings on $3.10 EPS, with a trailing P/E of 32.31 and an earnings date of October 21.
Analysts' average 12-month price target sits at $120.26, implying further upside. But Abbott's heart failure unit, while growing quickly, is one division inside a $46.6 billion revenue company still digesting a steep post-COVID diagnostics decline. ABT has underperformed the broader market by roughly 25 percentage points over the past year.
The Strategic Bet: Turning Hardware Into a Digital Platform The deeper signal is Abbott's shift from selling one-time implants to building a connected-care ecosystem — sensor plus app plus automated treatment plans. If that combination demonstrably cuts hospitalizations and earns premium reimbursement, it strengthens Abbott's pricing power across cardiovascular care. Investors should watch the October 21 earnings call for management's first comments on adoption targets and the revenue model behind the new software.